| Revenue growth | 22% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 24.1%, down from 31.8% YoY. |
| Demand visibility | Strong demand in International and India branded formulations. |
Growth
Revenue reached Rs. 80,170 mn (+22% YoY). Reported PAT fell 35.9% YoY to Rs. 9,398 mn.
Outlook
Organic capex of Rs. 5,852 mn this quarter. Focus on specialty portfolio and new US launches.
Risks
EBITDA margin contracted 770 bps YoY to 24.1%. Net debt increased to Rs. 59,041 mn.
Last quarter's promises, checked
Delivered
- Guided high teens revenue growth → delivered 22% YoY (= BEAT)
- Guided margins in excess of 24% → delivered 24.1% (= BEAT)
- Guided India outperformance vs IPM → delivered outpaced market (= BEAT)
Partly delivered
- Guided single digit US growth → delivered growth driven by 11 launches (= PARTIAL)
Investor Presentation filed with BSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,203.90
- Market cap
- ₹1,21,141 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 50.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Earnings Call Transcript: Key Takeaways
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
- Call
- Guides 10% growth
Zydus Lifesciences Q1 FY27 Results: Net Profit ₹939.8 Cr, Down 35.9% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹939.8 Cr · -35.9% YoY
Zydus Lifesciences Earnings Call: Key Takeaways
Zydus delivered strong Q4 FY26 results with 16% YoY revenue growth and record 33.7% EBITDA margins, driven by US specialty and India branded formulations.